^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GEM333

    i
    Other names: GEM333, GEM 333, GEM-333
    Associations

    News

    Trials
    Company:
    AvenCell Therap, BMS
    Drug class:
    CD3 agonist, CD33 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=36, Terminated, AvenCell Europe GmbH | Trial completion date: Dec 2020 --> Jun 2022 | Unknown status --> Terminated | Trial primary completion date: Jul 2020 --> Jun 2022; The actions and measures to be taken to restart the trial could not be implemented which made the premature termination inevitability.
    Trial completion date • Trial termination • Trial primary completion date
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    GEM333
    over4years
    Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, GEMoaB Monoclonals GmbH | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    GEM333